OncoEthix SA
http://www.oncoethix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OncoEthix SA
Merck’s Oncology Strategy: Digging In With Expansion Of Keytruda
With Keytruda, Merck has shown it has the wherewithal to compete in immuno-oncology against more experienced rivals. Now, as management outlined at ASCO, the company is digging its heels into the field, studying Keytruda in 30 tumor types and evaluating other early stage assets.
Biopharma Quarterly Dealmaking Statistics, Q4 2014
Biopharma financing increased 53% in Q4 to $8.8 billion; Actavis’ $65 billion takeover of Allergan topped the M&A activity, and Janssen led in dealmaking with six alliances.
Venture Funding Continues Upward Climb, But On The Backs Of Fewer Investors – BIO Report
Oncology companies have been garnering the most investment from venture capital firms over the last 10 years due to their high levels of innovation, according to a new report from the industry group.
Deals Shaping The Medical Industry, January 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice